Edward Lewis Tobinick is an American physician currently in full-time private practice in Los Angeles, California and he is an Assistant Clinical Professor of Medicine at the David Geffen School of Medicine at UCLA.[1] Dr. Tobinick is co-author of the recent case report documenting rapid clinical improvement in a patient with Alzheimer's disease following perispinal administration of etanercept[2] which has been received with considerable interest[3][1].
Tobinick has been issued patents for methods of perispinal administration, of certain recombinant DNA-derived (biologic) therapeutics including the TNF receptor fusion protein etanercept, for the treatment of certain neurologic disorders with widespread unmet medical need, including Alzheimer's disease; pain due to cancer metastasis to bone; severe, intractable, intervertebral disc-related pain and radiculopathy (including sciatica); and myasthenia gravis.[4] In addition, he originated the concept of the potential utility of etanercept, alone or in combination with oseltamivir for treatment of influenza (U.S. patent 6,419,934, filed September 5, 2000 [1]). For these novel treatment methods he has been issued multiple U.S. patents, including 6,015,557 (Tumor necrosis factor antagonists for the treatment of neurological disorders) [2]; 6,177,077 [3]; 6,419,934 [4]; and 6,982,089 [5]. In general, his concepts represent emerging therapeutic strategies supported by small pilot studies and expert reviews. (see 2007 Citations, below). [5]
Tobinick earned his M.D. from the UC San Diego School of Medicine in 1977.
Publications
- Tobinick E, Gross H. (2008). "Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration". Journal of Neuroinflammation 5 (2): 2. doi:. PMID 18184433.
- Tobinick E, Gross H, Weinberger A, Cohen H. (2006). "TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study". Medscape General Medicine 8 (2): 25f. PMID 16926764.
- Tobinick E. (2006). "The Cerebrospinal Venous System: Anatomy, Physiology, and Clinical Implications". Medscape General Medicine 8 (1): 53f. PMID 16915183.
- Tobinick E, Davoodifar S. (2004). "Efficacy of etanercept delivered by perispinal administration for chronic back and/or neck disc-related pain: a study of clinical observations in 143 patients". Curr Med Res Opin 20 (7): 1075–85. doi:. PMID 15265252.
- Tobinick E, Britschgi-Davoodifar S. (2003). "Perispinal TNF-alpha inhibition for discogenic pain.". Clinical Therapeutics 25 (4): 1211–18. doi:. PMID 12809967.
- Tobinick E. (2003). "Targeted etanercept for discogenic neck pain: uncontrolled, open-label results in two adults.". Swiss Med Wkly 133 (11-12): 170–177. PMID 12715286.
- Tobinick E. (2003 (August)). "Targeted etanercept for treatment-refractory pain due to bone metastasis: two case reports.". Clinical Therapeutics 25 (8): 2279–88. doi:. PMID 14512134.
- Tobinick E. (2004). "TNF-alpha inhibition for potential therapeutic modulation of SARS coronavirus infection.". Curr Med Res Opin 20 (1): 39–40. doi:. PMID 14741070.
- Tobinick, Edward; Richard Usatine, Ronald Moy, Daniel Siegel (1998). Skin Surgery: A Practical Guide. St. Louis: Mosby. ISBN 0-8151-7362-8.
References
- ^ a b UCLA Headlines Jan. 11, 2008 / UCLA Newsroom
- ^ Journal of Neuroinflammation | Full text | Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration
- ^ Journal of Neuroinflammation | Full text | Perispinal etanercept: Potential as an Alzheimer therapeutic
- ^ United States Patent 6,423,321
- ^ Tobinick's private practice
- Rosenberg P. (2006). "Editorial: Cytokine inhibition for treatment of Alzheimer's Disease". MedGenMed Neurology & Neurosurgery 8 (2): 1. link
External links
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)
